Enterologics

Enterologics is a development-stage company focused on the manufacturing, commercialization, and sales of new prescription pharmaceutical products. It specializes in developing probiotic biotherapeutic products for the treatment of gastrointestinal diseases, including pouchitis, irritable bowel syndrome, Crohn's disease, ulcerative colitis, and Clostridioides difficile infection. The company’s product under development, Escherichia coli M17, is actively being investigated with the FDA for a New Drug Application for the indication of chronic pouchitis.